A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen

Journal of Clinical Hypertension

Volumn 10, Issue 8, 2008, Pages 592-602

  Farkouh, Michael E ^a   Verheugt, Freek W A ^b   Ruland, Sean ^c   Kirshner, Howard ^d   Jeger, Raban ^e   Gitton, Xavier ^f   Krammer, Gerhard ^f   Stricker, Kirstin ^f   Sallstig, Peter ^f   Mellein, Bernhard ^f   Matchaba, Patrice ^f   Chesebro, James H ^g  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBUPROFEN; LUMIRACOXIB; NAPROXEN; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DRUG DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MULTICENTER STUDY; OSTEOARTHRITIS; PAIN ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; URINALYSIS; WEIGHT GAIN; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; MIDDLE AGED;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; CREATININE; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; FEMALE; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; NAPROXEN; PAIN MEASUREMENT;

EID: 52649131474     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.07802.x     Document Type: Article

References (28)

1. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81(9):646-656.
2. Jeger RV, Greenberg JD, Ramanathan K, et al. Lumiracoxib, a highly selective COX-2 inhibitor. Expert Review Clin Immunol. 2005;1:37-45.
3. Brater DC, Harris C, Redfern JS, et al. Renal effects of COX-2-selective inhibitors. Am J Nephrol. 2001;21:1-15.
4. Harris RC. Cyclooxygenase-2 and the kidney: Functional and pathophysiological implications. J Hypertens (Suppl). 2002;20(suppl 6):S3-S9.
5. Singh G, Miller JD, Huse DM, et al. Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol. 2003;30:714-719.
6. Farkouh ME, Kirshner H, Harrington RA, et al. TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: Randomised controlled trial. Lancet. 2004;364:675-684.
7. Hawkey CJ, Farkouh M, Gitton X, et al. Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib: Study design and patient demographics. Aliment Pharmacol Ther. 2004;20:51-63.
8. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. TARGET Study Group. Lancet. 2004;364:665-674.
9. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Publication No. 04-5230. National Institutes of Health; 2004. http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf. Accessed January 22, 2008.
10. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-1536.
11. Whitehead A, Simmonds M, Mellein B, et al. Blood pressure profile of lumiracoxib is similar to placebo in arthritis patients [abstract P309]. Osteoarthritis Cartilage. 2006;14(suppl 2):S168-S169.
12. Singh G, Miller JD, Lee FH, et al. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: Data from the third national health and nutrition examination survey. Am J Manag Care. 2002;8:S383-S391.
13. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153:477-484.
14. Whelton A, Fort JG, Puma JA, et al. SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001;8:85-95.
15. Schwartz JI, Vandormael K, Malice MP, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther. 2002;72:50-61.
16. Aw TJ, Haas SJ, Liew D, et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165:490-496.
17. Maillard M, Burnier M. Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2006;5:83-94.
18. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121:289-300.
19. Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine and enalapril. Am J Hypertens. 2000;13:1161-1167.
20. Whelton A, White WB, Bello AE, et al. SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-963.
21. MacDonald TM, Reginster J-Y, Richard D, et al. Reduced destabilization of blood pressure with lumiracoxib compared to ibuprofen in osteoarthritis patients with controlled hypertension treated with ACE inhibitor monotherapy [abstract 265]. Osteoarthritis Cartilage. 2007;15(suppl 3):C149.
22. Weaver ML, Flood DJ, Kimble EF, et al. Lumiracoxib demonstrates preferential distribution to inflamed tissue in the rat following a single oral dose: An effect not seen with other cyclooxygenase-2 inhibitors [abstract AB0044]. Ann Rheum Dis. 2003;62(suppl 1):378.
23. Scott G, Rordorf C, Reynolds C, et al. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet. 2004;43:467-478.
24. Hartmann S, Scott G, Rordorf C, et al. Lumiracoxib demonstrates high absolute bioavailability in healthy subjects [abstract P-99]. In: Tulunay FC, Orme M, eds. European Collaboration: Towards Drug Development and Rational Drug Therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. Berlin, Germany: Springer-Verlag; 2003:124.
25. Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: Similarities and differences. Scand J Rheumatol. 2004;33:1-6.
26. Bruehl S, Chung OY, Jirjis JN, et al. Prevalence of clinical hypertension in patients with chronic pain compared to nonpain general medical patients. Clin J Pain. 2005;21:147-153.
27. Lehmann R, Brzosko M, Kopsa P, et al. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: A 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr Med Res Opin. 2005;21:517-526.
28. Sheldon E, Beaulieu A, Paster Z, et al. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: A 13-week, randomized, double-blind comparison with celecoxib and placebo. Clin Ther. 2005;27:64-77.